Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q5010385> ?p ?o }
Showing triples 1 to 18 of
18
with 100 triples per page.
- Q5010385 subject Q6814492.
- Q5010385 abstract "A CETP inhibitor is a member of a class of drugs that inhibit cholesterylester transfer protein (CETP). They are intended to reduce the risk of atherosclerosis (a cardiovascular disease) by improving blood lipid levels. This category of drugs substantially increases HDL and reverse cholesterol transport. As of 2015, these drugs have generally failed in clinical trials, either causing a marked increase in deaths (torcetrapib), or having no meaningful clinical improvement despite HDL increases (dalcetrapib, evacetrapib).In testing: Anacetrapib, encouraging phase IIb interim results in 2010. Two phase III trials are running until 2017. TA-8995, Phase II results reported in 2015.Failed: Torcetrapib, failed in 2006 - excess deaths in phase III. Dalcetrapib, development halted in May 2012 when Phase III trials failed to show clinically meaningful efficacy. Evacetrapib, development discontinued in 2015 due to insufficient efficacy↑ ↑ ↑ ↑ ↑ ↑ ↑".
- Q5010385 thumbnail Torcetrapib.png?width=300.
- Q5010385 wikiPageWikiLink Q12252367.
- Q5010385 wikiPageWikiLink Q14878192.
- Q5010385 wikiPageWikiLink Q28749.
- Q5010385 wikiPageWikiLink Q389735.
- Q5010385 wikiPageWikiLink Q410020.
- Q5010385 wikiPageWikiLink Q419074.
- Q5010385 wikiPageWikiLink Q4750639.
- Q5010385 wikiPageWikiLink Q5210285.
- Q5010385 wikiPageWikiLink Q553129.
- Q5010385 wikiPageWikiLink Q6814492.
- Q5010385 wikiPageWikiLink Q7318217.
- Q5010385 wikiPageWikiLink Q7825530.
- Q5010385 comment "A CETP inhibitor is a member of a class of drugs that inhibit cholesterylester transfer protein (CETP). They are intended to reduce the risk of atherosclerosis (a cardiovascular disease) by improving blood lipid levels. This category of drugs substantially increases HDL and reverse cholesterol transport.".
- Q5010385 label "CETP inhibitor".
- Q5010385 depiction Torcetrapib.png.